32

BrainStorm

January 17, 2023

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

About This Episode

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm, host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative.  They discuss the immediate implications of the drug approval, how it will impact the Alzheimer’s movement, and what it means for the future of Alzheimer’s disease. 

Do you have feedback or an idea for the podcast? Send us a note at [email protected].
 

Support the show

BrainStorm Feed

116
September 21, 2026 | 27:31

Leading in Public, Caregiving in Private with Angela Williams

Angela Williams spent decades building a career that culminated in leading United Way Worldwide — a global network serving 48 million people across 36 countries

LISTEN NOW
115
September 1, 2026 | 26:33

The Calls You Can't Answer: Building a Voice Bridge for Dementia Caregivers with Kirstin Thomas

Caregivers of people with dementia know the toll of repetitive, anxiety-driven phone calls — sometimes dozens or even a hundred a day. On this episode

LISTEN NOW
114
August 18, 2026 | 23:44

Your Mouth, Your Brain - The Oral Health-Alzheimer's Connection with Dr. Rasetto

Your mouth may be doing more than you think — it could be a gateway to your brain. In this episode of BrainStorm, host

LISTEN NOW